Alyeska Investment Group
PCVX icon

Alyeska Investment Group’s Vaxcyte PCVX Stock Holding History

Alyeska Investment Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Sell
362,272
-73,309
-17% -$3.98M 0.05% 329
2026
Q1 		$25.3M Buy
435,581
+190,806
+78% +$10.4M 0.07% 289
2025
Q4 		$11.3M Hold
244,775
– – 0.03% 371
2025
Q3 		$8.82M Hold
244,775
– – 0.03% 394
2025
Q2 		$7.96M Buy
244,775
+80,135
+49% +$2.63M 0.03% 378
2025
Q1 		$6.22M Sell
164,640
-32,945
-17% -$2.63M 0.02% 349
2024
Q4 		$16.2M Sell
197,585
-21,246
-10% -$2.11M 0.06% 282
2024
Q3 		$25M Buy
+218,831
New +$19.7M 0.13% 215
2024
Q1 		– Sell
-25,000
Closed -$1.57M – 577
2023
Q4 		$1.57M Hold
25,000
– – 0.01% 388
2023
Q3 		$1.27M Hold
25,000
– – 0.01% 411
2023
Q2 		$1.25M Sell
25,000
-20,000
-44% -$948K 0.01% 441
2023
Q1 		$1.69M Hold
45,000
– – 0.01% 367
2022
Q4 		$2.16M Sell
45,000
-7,100
-14% -$279K 0.02% 310
2022
Q3 		$1.25M Hold
52,100
– – 0.01% 340
2022
Q2 		$1.13M Hold
52,100
– – 0.01% 455
2022
Q1 		$1.26M Buy
+52,100
New +$1.14M 0.01% 479

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group's PCVX Position: Q2 2026 in Review

Alyeska Investment Group reduced its Vaxcyte (PCVX) stake by 17% in Q2 2026, selling an estimated $3.98M and leaving 362,272 shares worth $21.1M. The position accounts for 0.05% of the portfolio, ranked #329.

Alyeska Investment Group first reported a position in PCVX in Q1 2022 and has held it in 16 quarters since. The position peaked at $25.3M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Alyeska Investment Group held 362,272 shares of Vaxcyte worth $21.1M as of Q2 2026.
  • Alyeska Investment Group sold 73,309 Vaxcyte shares in Q2 2026, an estimated $3.98M.
  • Vaxcyte made up 0.05% of Alyeska Investment Group's portfolio in Q2 2026, its #329 holding.
  • Alyeska Investment Group first reported a position in Vaxcyte in Q1 2022 and has held it in 16 quarters since.
  • Alyeska Investment Group's Vaxcyte position peaked at $25.3M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.